Skip to main content
OpenTrials
Completed

NCT Number: NCT02322944

China PEACE II: Quality Improvement for Acute Myocardial Infarction

This study aims to develop quality improvement strategies and relevant tools focusing on reperfusion therapy in patients with STEMI, and to evaluate their effectiveness via a hospital-level cluster randomized clinical trial, based on the nationally representative collaborative network of over 100 hospitals established in China PEACE retrospective study. In a baseline survey period, through consecutively recruiting all eligible inpatients and collecting relevant medical information, the performance of all participating hospitals before the implementation of the intervention will be assessed. During the following intervention period, 6-10 hospitals that show the strong willingness and ability to collaborate will be selected as "process optimization group". Their clinical pathways and team building will be re-organized for the purpose of quality improvement, and develop individualized treatment strategies and process. Meanwhile, other participating hospitals will be divided into intervention and control groups in a 1:1 ratio, in which the intervention group will take the treatment improvement strategy into implementation, while the control group will maintain the routine practice pattern. All hospitals will consecutively recruit qualified patients in the same method adopted in baseline period. Then the reperfusion rates and other performance measures will be compared among different groups (process optimization, intervention and control).

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Qinyang People's Hospital

Jiaozuo, Henan, China

About this study

This study aims to develop quality improvement strategies and relevant tools focusing on reperfusion therapy in patients with STEMI, and to evaluate their effectiveness via a hospital-level cluster randomized clinical trial, based on the nationally representative collaborative network of over 100 hospitals established in China PEACE retrospective study. The primary outcome measure is reperfusion rate among eligible patients with STEMI, and secondary ones include timeliness of primary PCI (D2B) and fibrinolytic therapy (D2N). the assessment is based on consecutively recruiting all eligible inpatients, as well as collecting relevant medical information via a case report form finished by local doctors and central medical record abstraction.

During the first study period, the baseline performance of all 100 participating hospitals before the implementation of the intervention will be assessed.

During the following period, 3-5 PCI-capable and 3-5 non-PCI capable hospitals that show the strong willingness and ability to collaborate will be selected as "process optimization group". Their clinical pathways and team building will be re-organized for the purpose of quality improvement, and develop individualized treatment strategies and process, including examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as pre-paid policy for fibrinolytic or PPCI, thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the Cath lab, interventional medical team gathering, etc.). Also, QI strategies and tools developed in the current study will be provided to these hospital, including training in standardized treatment pattern; building quality management team and determining improvement goals; periodical quality feedback report and regular quality meeting; tools like a wristband in order to remind all medical staff involved in the treatment process, workflow posters and cards, a CRF including a flowchart to inform the management steps, study website serving as the communication platform.

Meanwhile, other participating hospitals will be divided into intervention and control groups in a 1:1 ratio using minimization allocation, in which the intervention group will take the QI strategies and tools developed in the current study as mentioned above, while the control group will maintain the routine practice pattern. Then the outcome measures and other performance indicators will be compared among different groups (process optimization, intervention and control).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with STEMI who arrive at the hospital within 12 hours from the symptoms onset.

Exclusion criteria

  • Received reperfusionthrombolytic therapy before the index hospitalization;
  • AMI occurring during hospitalization;
  • Chest trauma resulting in secondary acute myocardial infarction.

Treatment and study plan

Quality improvement strategies and tools

Behavioral

Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.

Process optimization

Behavioral

Examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the cath lab, interventional medical team gathering, etc.) and systems (such as pre-paid policy for thrombolysis or PPCI)

Primary outcomes

  1. Reperfusion therapy rate

    Time frame: 24 hours after admission

    Reperfusion therapy rate is defined as utilization rate of thrombolytic therapy or primary PCI treatment among patients indicated with the reperfusion therapy.

Secondary outcomes

  1. Timeliness of primary PCI

    Time frame: 24 hours after admission

    The proportion of door to balloon (D2B) within 90 minutes among all patients receiving PPCI.

  2. Timeliness of thrombolytic therapy

    Time frame: 24 hours after admission

    The proportion of door to needle time (D2N) within 30 minutes among all patients receiving fibrinolytic therapy.

  3. Timeliness of primary PCI

    Time frame: 24 hours after admission

    Door to balloon (D2B) time

  4. Timeliness of thrombolytic therapy

    Time frame: 24 hours after admission

    Door to needle (D2N) time

Other outcomes

  1. In-hospital mortality

    Time frame: 10 days on average (during hospitalization)

    Proportion of in-hospital mortality or withdraw treatment due to a terminal status at discharge.

  2. Aspirin use within 24 hours

    Time frame: 24 hours after admission

    Proportion of aspirin use within 24 hours of admission among eligible patients

  3. Heparin use within 24 hours

    Time frame: 24 hours after admission

    Proportion of heparin use within 24 hours of admission among eligible patients

  4. Evaluation of left ventricular function

    Time frame: 24 hours after admission

    Proportion of left ventricular function evaluation within 24 hours of admission among all patients.

  5. β-blockers use during hospitalization

    Time frame: 10 days on average (during hospitalization)

    Proportion of β-blockers use during hospitalization among eligible patients.

  6. Statins use during hospitalization

    Time frame: 10 days on average (during hospitalization)

    Proportion of statins use during hospitalization among eligible patients.

  7. ACEI/ARB use during hospitalization

    Time frame: 10 days on average (during hospitalization)

    Proportion of ACEI/ARB use during hospitalization among eligible patients.

  8. Aspirin use at discharge

    Time frame: 10 days on average (during hospitalization)

    Proportion of aspirin use at discharge among eligible patients.

  9. Clopidogrel (or ticagrelor) use at discharge

    Time frame: 10 days on average (during hospitalization)

    Proportion of Clopidogrel (or ticagrelor) use at discharge among eligible patients.

  10. β-blockers use at discharge

    Time frame: 10 days on average (during hospitalization)

    Proportion of β-blockers use at discharge among eligible patients.

  11. ACEI/ARB use at discharge

    Time frame: 10 days on average (during hospitalization)

    Proportion of ACEI/ARB use at discharge among eligible patients.

  12. Statins use at discharge

    Time frame: 10 days on average (during hospitalization)

    Proportion of statins use at discharge among eligible patients.

Sponsors and collaborators

Lead sponsor

China National Center for Cardiovascular Diseases

Other Gov

Registry information

Official study title

China Patient-centered Evaluative Assessment of Cardiac Events II: Quality Improvement for Acute Myocardial Infarction

Acronym: PEACE-QI-AMI

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Dec 23, 2014
Registry last updated
Oct 24, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.